Advisory Research Inc Krystal Biotech, Inc. Transaction History

Advisory Research Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$96.0 - $128.29 $318,912 - $426,179	-3,322 Reduced 36.96%	5,667 $703,000
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $289,070 - $346,906	-2,664 Reduced 22.86%	8,989 $1.04 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $914,527 - $1.52 Million	11,653 New	11,653 $1.37 Million
Q4 2022 Feb 13, 2023	SELL	$63.14 - $79.9 $29,360 - $37,153	-465 Reduced 4.3%	10,354 $820,000
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $325,676 - $413,812	-5,022 Reduced 31.7%	10,819 $754,000
Q2 2022 Aug 17, 2022	SELL	$48.93 - $73.47 $141,407 - $212,328	-2,890 Reduced 15.43%	15,841 $1.04 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $644,260 - $893,587	12,392 Added 195.49%	18,731 $1.25 Million
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $252,355 - $559,353	6,339 New	6,339 $443,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.